Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:MDNA)

Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

GlobeNewswire April 30, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

GlobeNewswire April 28, 2025

Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 22, 2025

Medicenna to Present at Jones Healthcare and Technology Innovation Conference

GlobeNewswire April 1, 2025

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswire March 26, 2025

Medicenna Reports MDNA11's Compelling Anti-Cancer Activity is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

GlobeNewswire February 25, 2025

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

GlobeNewswire February 13, 2025

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

GlobeNewswire February 5, 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire December 13, 2024
View More News ››

Opinion & Analysis (TSX:MDNA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:MDNA)

Nice close

   Trending nicely on low volume. Support is moving up with the push. Very nice.. if this gets hit will any level of serious...
Pocketfulofhope - May 1, 2025

Great news and market is buying

This seems to always trade light but she is trending up. They have recently been involved in investors awareness campaigns  so maybe...
Pocketfulofhope - April 28, 2025

Interesting news

Could lead to stronger investor awareness and hopefully support.  
Pocketfulofhope - April 1, 2025

Started a position today.

Looks like she might trend up for a bit.. great luck to all
Pocketfulofhope - March 13, 2025

Info for Newbies

https://t.co/bP1YwDIneR
ENEMENEMYNEMO - January 5, 2025

JP Morgan Summit

Stay tuned for news on breakthroughs next week!
ENEMENEMYNEMO - January 5, 2025
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »